These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 15891995

  • 1. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
    Hicks DG, Yoder BJ, Pettay J, Swain E, Tarr S, Hartke M, Skacel M, Crowe JP, Budd GT, Tubbs RR.
    Hum Pathol; 2005 Apr; 36(4):348-56. PubMed ID: 15891995
    [Abstract] [Full Text] [Related]

  • 2. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A.
    Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
    [Abstract] [Full Text] [Related]

  • 3. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
    Mueller RE, Parkes RK, Andrulis I, O'Malley FP.
    Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
    [Abstract] [Full Text] [Related]

  • 4. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K, Trojanec R, Kolár Z, Cwiertka K, Cernáková I, Mihál V, Hajdúch M.
    Neoplasma; 2006 Apr; 53(5):393-401. PubMed ID: 17013533
    [Abstract] [Full Text] [Related]

  • 5. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [Abstract] [Full Text] [Related]

  • 6. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
    Konecny GE, Pauletti G, Untch M, Wang HJ, Möbus V, Kuhn W, Thomssen C, Harbeck N, Wang L, Apple S, Jänicke F, Slamon DJ.
    Breast Cancer Res Treat; 2010 Apr; 120(2):481-9. PubMed ID: 20130985
    [Abstract] [Full Text] [Related]

  • 7. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, Yin PL, Chen M.
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [Abstract] [Full Text] [Related]

  • 8. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
    Jacobson KK, Morrison LE, Henderson BT, Blondin BA, Wilber KA, Legator MS, O'Hare A, Van Stedum SC, Proffitt JH, Seelig SA, Coon JS.
    Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
    [Abstract] [Full Text] [Related]

  • 9. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
    Villman K, Sjöström J, Heikkilä R, Hultborn R, Malmström P, Bengtsson NO, Söderberg M, Saksela E, Blomqvist C.
    Acta Oncol; 2006 May; 45(5):590-6. PubMed ID: 16864174
    [Abstract] [Full Text] [Related]

  • 10. A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening andtreatment.
    Hansel DE, Ashfaq R, Rahman A, Wanzer D, Yeo CJ, Wilentz RE, Maitra A.
    Am J Clin Pathol; 2005 Jan; 123(1):28-35. PubMed ID: 15762277
    [Abstract] [Full Text] [Related]

  • 11. Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.
    Park K, Han S, Gwak GH, Kim HJ, Kim J, Kim KM.
    Breast Cancer Res Treat; 2006 Aug; 98(3):337-42. PubMed ID: 16502015
    [Abstract] [Full Text] [Related]

  • 12. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
    Murphy AJ, Hughes CA, Barrett C, Magee H, Loftus B, O'Leary JJ, Sheils O.
    Cancer Res; 2007 Mar 15; 67(6):2893-8. PubMed ID: 17363613
    [Abstract] [Full Text] [Related]

  • 13. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Tibau A, López-Vilaró L, Pérez-Olabarria M, Vázquez T, Pons C, Gich I, Alonso C, Ojeda B, Ramón y Cajal T, Lerma E, Barnadas A, Escuin D.
    Neoplasia; 2014 Oct 15; 16(10):861-7. PubMed ID: 25379022
    [Abstract] [Full Text] [Related]

  • 14. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
    Järvinen TA, Tanner M, Bärlund M, Borg A, Isola J.
    Genes Chromosomes Cancer; 1999 Oct 15; 26(2):142-50. PubMed ID: 10469452
    [Abstract] [Full Text] [Related]

  • 15. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    Scandinavian Breast Group Trial 9401Laboratory of Cancer Biology, Institute of Medical Technology, and Department of Oncology, Tampere University and Tampere University Hospital, Tampere, Finland., Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.
    J Clin Oncol; 2006 Jun 01; 24(16):2428-36. PubMed ID: 16682728
    [Abstract] [Full Text] [Related]

  • 16. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
    Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, Hellwig B, Rahnenführer J, Hengstler JG, Gehrmann MC.
    Clin Cancer Res; 2010 Apr 15; 16(8):2391-401. PubMed ID: 20371687
    [Abstract] [Full Text] [Related]

  • 17. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience.
    Tubbs RR, Hicks DG, Cook J, Downs-Kelly E, Pettay J, Hartke MB, Hood L, Neelon R, Myles J, Budd GT, Moore HC, Andresen S, Crowe JP.
    Diagn Mol Pathol; 2007 Dec 15; 16(4):207-10. PubMed ID: 18043283
    [Abstract] [Full Text] [Related]

  • 18. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
    Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdóttir K, Olsen KE, Mouridsen H, Ejlertsen B, Danish Breast Cancer Cooperative Group.
    J Clin Oncol; 2005 Oct 20; 23(30):7483-90. PubMed ID: 16234514
    [Abstract] [Full Text] [Related]

  • 19. The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy.
    Kawachi K, Sasaki T, Murakami A, Ishikawa T, Kito A, Ota I, Shimizu D, Nozawa A, Nagashima Y, Machinami R, Aoki I.
    Pathol Res Pract; 2010 Mar 15; 206(3):156-62. PubMed ID: 20089371
    [Abstract] [Full Text] [Related]

  • 20. Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes.
    Varga Z, Moelans CB, Zuerrer-Hardi U, Ramach C, Behnke S, Kristiansen G, Moch H.
    Breast Cancer Res Treat; 2012 Jun 15; 133(3):929-35. PubMed ID: 22083232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.